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The antibody responses of CBA/J mice infected intranasally (i.n.) with either the attenuated KyA strain or the pathogenic
RacL11 strain of equine herpesvirus 1 (EHV-1) or immunized with recombinant glycoprotein D (rgD) were investigated using
the ELISPOT assay to measure EHV-1-specific antibody-secreting cells (ASC) in the regional lymphoid tissue of the
respiratory tract. IgG, IgA, and IgM ASC specific for EHV-1 were detected in the mediastinal lymph nodes (MLN) and lungs
2 weeks after i.n. infection with EHV-1 strain KyA or RacL11, or immunization with heat-killed KyA or rgD. EHV-1-specific ASC
were present in the MLN and lungs at 4 and 8 weeks, but declined in frequency by fivefold in the lung at 8 weeks. However,
i.n. immunized (2 3 106 pfu KyA or 50 mg rgD/mouse) mice infected at 8 weeks with pathogenic EHV-1 RacL11 resisted
challenge and showed eight- and tenfold increases in MLN ASC and lung ASC, respectively, by 3 days after challenge. In
contrast to the intranasal route of immunization, intraperitoneal immunization yielded ASC frequencies in the MLN and lungs
that were only slightly above those of nonimmunized control mice. These data indicate that immunization with infectious or
heat-killed EHV-1 KyA, or rgD, induces significant levels of virus-specific ASC both in the MLN and lungs, a specific memory
B-cell response, and long-term protective immunity. The finding that the numbers of ASC induced by the pathogenic strain
versus the attenuated strain of EHV-1, which were virtually identical, indicated that the ability to generate a B-cell response
is independent of and does not contribute to EHV-1 virulence. © 2000 Academic PressINTRODUCTION
Equine herpesvirus type 1 (EHV-1), a major pathogen
of economic importance in horses, causes fetal abor-
tions, respiratory illness, and neurological diseases
(Allen and Bryans, 1986; O’Callaghan and Osterrieder,
1999). EHV-1 is distributed worldwide, and infections can
occur year-round, with nasal discharge being the main
source of infectious virus. Natural immunity in the horse
appears to be short-lived, and the efficacy of available
vaccines is questionable (Burki et al., 1990; Onions, 1991;
Hannant et al., 1993; Ellis et al., 1995; Gilkerson et al.,
1997). One of the current approaches to develop a new
generation of EHV-1 vaccines is based on the use of
envelope glycoproteins as immunogens. In this regard,
definition of the immune effector mechanisms induced
by vaccination and the identification of protective viral
glycoproteins are important (Guo et al., 1989; Stokes et
al., 1989; Guo et al., 1990; Love et al., 1993; Osterrieder et
al., 1994, 1995; Tewari et al., 1994, 1995; Stokes et al.,
1996a,b; Neubauer et al., 1997; Osterrieder et al., 1997;
Stokes et al., 1997; Matsumura et al., 1998; Packiarajah et
al., 1998; Zhang et al., 1998; Ruitenberg et al., 1999). For
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482equine herpesviruses, which have a highly cell associ-
ated viremia (Gleeson and Coggins, 1980; Allen et al.,
1999), both antibody and cellular immune responses are
likely to be important. Thus, an essential criterion for
choosing candidates for an effective subunit vaccine
should be a viral protein that elicits responses in both
immunological compartments.
The initial infection with many viral pathogens occurs
at mucosal surfaces such as the respiratory tract. There-
fore, mucosal immunity is important in controlling the
entry and spread of viral pathogens during respiratory or
localized infection. The best-studied regions responsible
for induction of mucosal immune responses are the
discrete lymphoid follicles in the intestine and respira-
tory tract (Bienenstock, 1984; Marshall et al., 1989,
McGhee and Kiyono, 1999). IgA synthesized by local
plasma cells is the principal mucosal antibody. The IgA
dimers are able to bind to the polymeric immunoglobulin
receptor on the basolateral surface of epithelial cells that
line the mucous membrane (Mostov, 1994). While muco-
sal plasma cells tend to make antibodies of the IgA
class, the systemic lymphoid tissue tends toward IgG
production (Lamm, 1997), reflecting the functional differ-
ences of the antibody isotypes at the different sites.
Protective immunity against reinfection with respira-
tory viral pathogens has traditionally been correlated
with antibody (Palache et al., 1993). Secretory IgA (sIgA)
may function by neutralization of virus attachment and/or
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483B-CELL RESPONSE TO EHV-1 BY ELISPOTentry (Armstrong and Dimmock, 1992) or inhibit viral
replication or assembly within the intracellular compart-
ment (Mazanec et al., 1992; Burns et al., 1996). Virus-
specific sIgA can be demonstrated in local secretions
following infection with respiratory syncytial virus (McIn-
tosh et al., 1979), influenzaviruses (Brown et al., 1985;
Gorse et al., 1988), herpes simplex virus type 2 (HSV-2)
(Milligan and Bernstein; 1995), and parainfluenzavirus
(Sangster et al., 1995). However, the techniques utilized
to measure the local antibodies are often very insensi-
tive.
The mechanisms of cellular and humoral immune re-
sponses to EHV-1 infection in the respiratory tract are
poorly understood (Allen et al., 1999). Our previous stud-
es demonstrate that i.n. immunization with either live
HV-1 strain KyA or rgD provides efficient protection
gainst challenge with pathogenic EHV-1 (Colle et al.,
996; Smith et al., 1998), as compared to the partial
rotection induced by immunization with the same anti-
ens via the intraperitoneal (ip) route (Zhang et al., 1998).
In this report, the local antibody responses of CBA/J
ice infected i.n. with EHV-1 strain KyA or immunized
ith rgD were investigated using the ELISPOT assay to
etermine EHV-1-specific antibody secreting cells (ASC)
n mediastinal lymph nodes (MLN) and cervical lymph
odes (CLN) as well as in the lung and spleen. The
esults demonstrated that immunization with EHV-1 KyA,
eat-killed KyA (HK-KyA), or rgD is capable of inducing
ignificant numbers of specific ASC in both the lung and
he MLN. In addition, these immunizations are capable of
nducing memory B cells that may be restimulated by
hallenge with EHV-1.
RESULTS
ptimization of the ELISPOT assay
To establish the basic parameters for detecting EHV-
-specific ASC, splenocytes were isolated from CBA/J
ice and stimulated with LPS (Wolcott et al., 1995). After
to 5 days, ASC were detected by ELISPOT assay
dapted to determine the number of cells producing
HV-1-specific antibodies and to identify the antibody
sotypes. Using a range of cell concentrations from 5 3
04 to 5 3 106/well, and a range of antigen concentra-
ions from 10 to 200 mg of EHV-1-infected cell lysate/well,
he optimal conditions were found to be 2 3 105 cells and
n infected cell lysate concentration of 50 mg/well. Un-
stimulated splenocytes contained no detectable EHV-1-
specific ASC at any concentration of cell lysate or cell
numbers tested (data not shown).
Frequencies of ASC from the lung, MLN, and CLN of
EHV-1-infected CBA/J miceAn important component of the protective immune
response against EHV-1 infection in mice is the pres-ence of virus-specific antibody in the upper respiratory
tract (Colle et al., 1996; Zhang et al., 1998). Therefore, it
was important to determine the magnitude and charac-
teristics of the B-lymphocyte response to infectious
EHV-1 KyA, which induces protection to challenge with
the pathogenic RacL11 strain (Colle et al., 1996; Zhang et
al., 1998). In addition, the B-cell response elicited by
immunization with HK-KyA and rgD, which also induce
protection (Zhang et al., 1998), was evaluated.
Initially, the response in the draining MLN of mice
immunized i.n. with KyA, HK-KyA, or rgD was determined
at 2, 4, 8, and 24 weeks postimmunization (Fig. 1). By 2
weeks, EHV-1-specific ASC were present in the MLN of
all three groups (Fig. 1A). There were no detectable ASC
FIG. 1. The frequency of ASC from the MLN of CBA/J mice at: 2 weeks
(A); 4 weeks (B); and 8 weeks (C) after immunization. CBA/J mice were
immunized i.n. with rgD (50 mg), EHV-1 KyA (5 3 106 pfu), HK-EHV-1 KyA
(56°C for 1 h, equivalent to 5 3 106 pfu prior to inactivation), or culture
edium or GST (50 mg) as control. The frequencies of EHV-1-specific
SC were determined at a concentration of 2 3 105 MLN lymphocytes/
well. Data show the average ASC frequencies from 5 mice/group,
representative of three independent experiments, for a total of 15
animals. Error bars represent the standard deviation from the means
for each group. The significance of differences between experimental
and control groups was determined by the Student’s two-tailed t test.in control animals immunized with culture medium. Im-
portantly, the GST component of the rgD construct did
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484 ZHANG ET AL.not elicit EHV-1-specific ASC above background levels,
even though it is capable of eliciting a low level of
nonspecific protection against EHV-1 RacL11 challenge
(Zhang et al., 1998). Of the three groups, infectious EHV-1
yA was the most effective in inducing virus-specific
SC (P , 0.005 for IgA ASC compared to the HK-KyA and
gD), followed by rgD and HK-KyA. There was no signif-
cant difference between the numbers of ASC generated
y rgD and HK-KyA. In the case of all groups, the relative
requencies of ASC secreting EHV-1-specific antibodies
ere approximately the same. Analysis of the MLN at 4
eeks following infection (Fig. 1B) revealed that specific
SC secreting IgG, IgA, or IgM were still present, indi-
ating that EHV-1-specific plasma cells persisted in the
egional LN after the virus was cleared from the lungs.
fter 8 weeks postimmunization, ASC specific for EHV-1
ropped to background levels (Fig. 1C).
Demonstrating the presence of EHV-1-specific ASC
ithin the MLN is important, because this is the likely
ite where the immune response is initiated (Smith et
al., 1998). However, antibody-mediated protection
gainst infection would be most effective if the ASC
ere present in the lungs themselves. Therefore, lym-
hocytes were isolated from the lung by enzymatic
igestion, and analyzed for EHV-1-specific ASC. It
hould be noted that the enzymatic digestion process
esults in the isolation of lymphocytes both from in-
lammatory infiltrates into the lung tissue, and also
rom mucosal-associated lymphoid tissues (MALT),
istinct from the MLN. High frequencies of EHV-1-
pecific ASC secreting IgG, IgA, or IgM were detected
n the lung-derived lymphocyte population (Fig. 2A). By
weeks, however, the frequencies of lung-derived
SC had decreased approximately sixfold (Fig. 2B),
ut were still present at levels similar to those de-
ected in the MLN at the same time point. The num-
ers of specific ASC present in mice immunized with
ive KyA or rgD were higher than those of mice immu-
ized with HK-KyA or control antigens (Fig. 2C).
It is clear from the studies of the CD81 T-cell-mediated
CTL response to EHV-1 that the distribution of the effec-
tor cell populations is compartmentalized. High CTL re-
sponses can be detected in the MLN and the lung, but
not in the CLN (Smith et al., 1998). This finding suggests
that there may be an underlying regulation of the immune
response within different lymphoid tissues, but it is not
clear if this is limited to the CD81 T-cell subpopulation, or
if it applies to other responding lymphocytes as well.
Therefore, the ASC responses from the CLN and MLN of
mice immunized i.n. with the above-mentioned three
antigens were compared. The results (Fig. 3) demon-
strated that the ASC secreting IgG, IgA, or IgM specific
for EHV-1 generated from the CLN were present in all
three groups by 2 weeks (Fig. 3A). EHV-1 KyA was the
most effective, followed by rgD. The frequencies of ASCfrom CLN declined thereafter, but EHV-1-specific ASC
were still present after 4 weeks (Fig. 3B).
Frequencies of ASC in CBA/J mice induced by
different strains of EHV-1
While EHV-1 strain KyA is nonpathogenic, the RacL11
strain causes severe pneumonitis in CBA/J mice (Smith
et al., 1998; Zhang et al., 1998). It is possible the pathol-
ogy may have an immunological basis, and that a sub-
optimal B-cell response to pathogenic EHV-1 may ex-
plain the more severe disease. However, as shown in
Figure 4, both KyA and RacL11 strains were capable of
inducing, in both lung tissue and MLN, similar levels of
ASC specific for EHV-1. These findings indicated that
both pathogenic and nonpathogenic EHV-1 strains are
able to induce similar B-cell responses in CBA/J mice,
FIG. 2. The frequency of ASC from the lungs of CBA/J mice at 2
weeks (A), 4 weeks (B), and 8 weeks (C) after immunization. CBA/J mice
were immunized i.n. with rgD (50 mg), EHV-1 KyA (5 3 106 pfu), HK-KyA
56°C for 1 h, equivalent to 5 3 106 pfu prior to inactivation), or culture
edium or GST (50 mg) as control. EHV-1-specific ASC frequencies
were estimated as described under Materials and Methods. Data show
the average ASC frequencies from 5 mice/group, representative of
three independent experiments, for a total of 15 animals.and that the disease is independent of the ability to
induce specific ASC.
ted as
f xperime
485B-CELL RESPONSE TO EHV-1 BY ELISPOTDuration of EHV-1-specific ASC responses
For protection against respiratory EHV-1 infection, it
was important to determine the duration of the long-term
memory B cells in the MLN and lungs. Mice were immu-
nized with infectious EHV-1 KyA, HK-KyA, or rgD, and
lymphocytes isolated from MLN were analyzed at 2, 4, 8,
and 24 weeks after immunization (Fig. 5). The data re-
FIG. 3. Comparison of ASC responses in the MLN and CLN of mice a
i.n. with infectious EHV-1 KyA (5 3 106 pfu), HK-EHV-1 KyA (56°C for 1 h,
or GST (50 mg) as control. EHV-1-specific ASC frequencies were estima
requencies from 5 mice/group, representative of three independent evealed that EHV-1 induced an antibody response con-
sisting of all three major isotypes. It was found that ASCsecreting IgG, IgA, and IgM specific for EHV-1 were
present at 4 and 8 weeks, but declined by 24 weeks (Fig.
5). As expected, the greatest decline was in IgM. Al-
though immunization with infectious EHV-1 KyA gave the
greatest response initially, the pattern of decline of ASC
was similar for all three antigens. The duration of the
B-cell response in the lungs was also examined (Fig. 6).
ks (A) and 4 weeks (B) after immunization. CBA/J mice were immunized
lent to 5 3 106 pfu prior to inactivation), rgD (50 mg), or culture medium
described under Materials and Methods. Data show the average ASC
nts, for a total of 15 animals.t 2 wee
equivaHigh frequencies of ASC secreting EHV-1-specific IgG,
IgA, and IgM were present in the lungs at 2 weeks after
a ASC
e
f
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486 ZHANG ET AL.immunization. By both 4 and 8 weeks, the frequency of
ASC in the lungs decreased approximately five- to sixfold
and declined further by 24 weeks. Although the levels of
EHV-1-specific ASC generated in response to HK-KyA or
rgD were not as high as those for infectious KyA, the
pattern of duration and decline was similar.
Systemic immunization does not induce a significant
EHV-1-specific ASC response in the lung
Our previous work indicated that intraperitoneal (ip)
immunization with EHV-1 preparations was effective in
FIG. 4. Comparison of ASC frequencies of mice immunized i.n. with p
i.n. with infectious EHV-1 KyA (1.5 3 106 pfu), RacL11 (1.5 3 106 pfu), o
s described under Materials and Methods. Data show the average
xperiments, for a total of 15 animals.
FIG. 5. Duration of EHV-1-specific ASC production in MLN of mice
infectious EHV-1 KyA (5 3 106 pfu), HK-EHV-1 KyA (56°C for 1 h, equival
(50 mg) as control. At 0, 2, 4, 8, and 24 weeks after immunization, th
requencies were estimated as described under Materials and Methods. Data
f three independent experiments, for a total of 15 animals.inducing a humoral immune response, but did not elicit
protection against challenge with pathogenic RacL11
(Zhang et al., 1998). This observation implied that the
immune response elicited by this route of immunization
was ineffective. To address the relative efficacy of this
route of immunization, groups of mice were immunized ip
with infectious EHV-1 KyA, HK-KyA, or rgD, and the num-
bers of EHV-1-specific ASC in the lung, MLN, and spleen
were determined. The numbers of EHV-1-specific ASC in
the MLN and lungs of mice immunized ip were only
slightly above those of control mice at both 2 (Table 1)
nic RacL11 or nonpathogenic EHV-1 KyA. CBA/J mice were immunized
e medium as control. EHV-1-specific ASC frequencies were estimated
frequencies from 5 mice/group, representative of three independent
ized with EHV-1 preparations. CBA/J mice were immunized i.n. with
3 106 pfu prior to inactivation), rgD (50 mg), or culture medium or GST
hocytes isolated from MLN were generated and EHV-1-specific ASCathoge
r culturimmun
ent to 5
e lympshow the average ASC frequencies from 5 mice/group, representative
s. Data
487B-CELL RESPONSE TO EHV-1 BY ELISPOTand 4 weeks (data not shown) after immunization. The
nonspecific activation of ASC within the MLN by GST
alone was not reflected in the lung or spleen. In contrast,
a large number of ASC could be detected in the spleens
of these mice (Table 1). These data support our previous
findings about the superiority of the intranasal route of
inoculation and indicate that little, if any, ASC response is
generated in either the lung or MLN of mice immunized
by the ip route.
Recall of memory B-cell responses in mice
immunized with EHV-1 KyA and challenged with
pathogenic EHV-1 RacL11
To examine the EHV-1-specific memory B-cell re-
sponse, groups of mice were challenged 8 weeks after
immunization with pathogenic EHV-1 RacL11 by the i.n.
route. On Day 3 postchallenge, the MLN and lungs were
assayed for EHV-1-specific ASC (Fig. 7). The ASC re-
sponses of the lungs were greater than those of the
MLN, and mice immunized with rgD showed the highest
frequencies of EHV-1-specific ASC. The ASC frequencies
in both lung and MLN were five- to tenfold greater than
those observed 8 weeks after immunization in nonchal-
lenged mice. The observation that challenge infection
induced high frequencies of EHV-1-specific ASC 8 weeks
FIG. 6. Duration of EHV-1-specific ASC in lung tissue of mice immun
EHV-1 KyA (5 3 106 pfu), HK-EHV-1 KyA (56°C for 1 h, equivalent to 5 3
as control. At 0, 2, 4, 8, and 24 weeks after immunization, the lymphocyt
frequencies were estimated as described under Materials and Method
of three independent experiments, for a total of 15 animals.after immunization indicated that a substantial EHV-1-
specific memory B-cell response had been established.DISCUSSION
The solid-phase immunoenzymatic technology desig-
nated ELISPOT or ELISA plaque assay has enhanced the
enumeration of lymphocytes which secrete antibodies
that specifically interact with a given antigen (Czerkinsky
et al., 1983; Sedgwick and Holt, 1983; Czerkinsky et al.,
1988). The ELISPOT technique has been used in recent
years to assess the efficacy of vaccines against bacterial
(Herrington et al., 1990; Holmgren et al., 1992; Hone et al.,
1992; Wenneras et al., 1992), viral (Kobayashi et al., 1994;
Schwartz et al., 1994; Carson et al., 1995; Isolauri et al.,
1995; Moldoveanu et al., 1995), and parasitic pathogens
(Fievet et al., 1993).
In the case of respiratory viral pathogens, the virus
enters the host via the mucosal surfaces of the upper
respiratory tract. The immune response is subsequently
generated in the regional lymphoid tissues. Mature B
lymphocytes are activated within germinal centers, emi-
grate via the efferent lymphatics, traffic to the blood
stream via the thoracic duct into the vena cava, and
ultimately home to the mucosal lymphoid tissues
(McGhee and Kiyono, 1999). During the migration pro-
cess, activated B cells capable of differentiation to ASC
can be detected in the blood and peripheral tissues.
ELISPOT assays reveal that ASC appear in the blood 4 to
th EHV-1 preparations. CBA/J mice were immunized i.n. with infectious
fu prior to inactivation), rgD (50 mg), or culture medium or GST (50 mg)
isolated from lungs (see Materials and Methods). EHV-1-specific ASC
show the average ASC frequencies from 5 mice/group, representativeized wi
106 p
es were5 days after the onset of infection, peak around Day 7,
and then disappear by 2 to 4 weeks (Arvilommi, 1996;
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488 ZHANG ET AL.Sjolander et al., 1996). However, ASC remain within the
regional lymphoid tissues and the bone marrow for an
extended period (McGhee and Kiyono, 1999).
In this study, we provide evidence that intranasal im-
munization with attenuated EHV-1 KyA, heat-killed EHV-1
KyA, or EHV-1 recombinant glycoprotein D induces a
significant virus-specific ASC response, which can be
detected in the lung and draining mediastinal (MLN) and
cervical lymph nodes (CLN). The results show that EHV-
1-specific ASC secreting IgM, IgG, or IgA are elevated
during the early stage of the respiratory infection or
following immunization. ASC isolated from the lung,
MLN, and CLN peak at 2 weeks postimmunization and
remain detectable at these sites at 24 weeks postimmu-
nization. However, in contrast to the EHV-1-specific CTL
response, which is confined exclusively to the MLN
(Smith et al., 1998), no significant differences were ob-
tained between the ASC generated in MLN and CLN,
TABLE 1
EHV-1 Specific ASC Following Systemic Immunization
Immunogens IgG IgA IgM
Numbers of ASC in 2 3 105 cells in MLNa
KyA 17.7 (1.15) 19.0 (3.61) 11.7 (1.15)
K-KyA 18.7 (1.15) 19.7 (2.08) 14.3 (0.58)
gD 23.3 (3.06) 22.3 (1.53) 16.3 (1.53)
ST 15.7 (1.53) 16.0 (2.00) 15.3 (1.53)
edium 5.7 (0.58) 4.7 (0.58) 3.7 (1.53)
Numbers of ASC in 2 3 105 cells in lungsa
KyA 22.0 (1.00) 18.3 (1.53) 13.7 (1.53)
K-KyA 20.3 (1.15) 21.0 (1.00) 18.3 (0.58)
gD 24.0 (1.73) 22.0 (5.29) 16.7 (1.15)
ST 16.0 (3.46) 8.3 (0.58) 6.0 (1.00)
edium 13.7 (0.58) 8.7 (1.15) 6.3 (1.15)
Numbers of ASC in 2 3 105 cells in spleensa
KyA 157.0 (5.29) 114.7 (6.03) 137.7 (7.64)
HK-KyA 132.7 (16.56) 89.3 (6.11) 139.7 (5.86)
rgD 118.7 (7.02) 101.0 (5.00) 111.7 (5.51)
GST 33.7 (8.62) 21.0 (3.61) 18.7 (2.52)
Medium 17.7 (1.53) 13.3 (2.08) 15.7 (4.51)
LPS stimulated in vitro 218.3 (6.03) 242.3 (8.50) 166 (6.24)
Note. Frequencies of EHV-1 specific ASC in the MLN, lung, and
spleen of mice immunized systemically. CBA/J mice were immunized
intraperitoneally with infectious EHV-1 KyA (5 3 106 pfu), HK-EHV-1 KyA
56°C for 1 h, equivalent to 5 3 106 pfu prior to inactivation), rgD (50
mg), or culture medium or GST (50 mg) as control. At 2 weeks after the
mmunization, mice were terminated, and lymphocytes isolated from
ungs, MLN, and spleen were assayed for EHV-1-specific ASC as
escribed under Materials and Methods. As a positive control, LPS
as added to the splenocyte cultures as described under Materials
nd Methods.
a The standard deviations are given in parentheses.which indicates that there is no compartmentalization of
the EHV-1-specific B-cell response. This suggests thatthe mechanisms for generating EHV-1-specific ASC and
CTL responses are distinct. A potential explanation for
this difference may be the involvement of the nasal-
associated lymphoid tissue, which is involved in dissem-
inating antigen-sensitized lymphocytes to mucosal and
nonmucosal lymphoid tissues through the CLN, which
drain the head and neck (Hameleers et al., 1991; Wu and
Russell, 1993; Wu et al., 1997).
The ASC induced by the pathogenic RacL11 strain
versus the attenuated KyA strain of EHV-1 were iden-
tical, indicating that the ability to generate a B-cell
response was independent of and did not contribute to
EHV-1 virulence. In addition, the numbers of EHV-1-
specific ASC generated by immunization with rgD and
HK-KyA were similar to those generated by infection
with virus. Regardless of the immunization strategy,
there were no significant differences in the immuno-
globulin isotypes elicited after 2 weeks, consistent
with our previous results (Zhang et al., 1998). Further-
more, direct immunization of the respiratory mucosa
proved to be the most effective method to induce
EHV-1-specific ASC synthesizing IgA, IgG, and IgM.
These findings indicate that all forms of immunogen
studied proved to be effective as vaccines against
respiratory EHV-1 infection (Zhang et al., 1998). This
was reflected by the ability of these immunogens to
induce ASC secreting specific antibodies of all major
immunoglobulin classes (this study). In addition, the
route of administration of a suitable EHV-1 immunogen
appeared to be an important consideration, whether
the immunogen is presented in the form of a replicat-
ing virus or a recombinant protein. Indeed, systemic
immunization with rgD by either the subcutaneous
route (Zhang et al., 1998) or the intraperitoneal route
(unpublished data) induces protection, but the level of
protection is 10- to 100-fold less effective in reducing
challenge virus titers as compared to immunization by
the intranasal route (Zhang et al., 1998).
An important issue is whether memory B cells remain
in the tissues of the respiratory tract following immuni-
zation. Challenge of mice with pathogenic EHV-1 RacL11
at 8 weeks following immunization with infectious EHV-1
KyA or rgD induced significant levels of ASC in the lungs
and mediastinal lymph nodes, as compared to naı¨ve
controls. These findings demonstrate the existence of
memory B cells and the ability to recall the EHV-1-spe-
cific B-cell response following reinfection. Overall, our
findings show that a substantial number of the EHV-1-
specific ASC appear in the lungs and draining lymph
nodes after intranasal immunization. Also, immunization
by the respiratory route is optimal to achieve antibody-
dependent protection in the mouse model, which closely
mimics the natural infection in the horse (Awan et al.,
1990, 1991).
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489B-CELL RESPONSE TO EHV-1 BY ELISPOTMATERIALS AND METHODS
Virus and cell culture. EHV-1 strain Kentucky A (KyA)
was grown at low multiplicity (m.o.i. 5 0.05 pfu/cell) in
L-M murine fibroblasts, as described previously (Perdue
et al., 1974). EHV-1 strain RacL11, a kind gift of Dr. Anton
Mayr (Institute for Medical Microbiology, Infectious and
Epidemic Disease, Ludwig-Maximilian-University, Mu-
nich, Germany) was grown at an m.o.i. 5 0.05 pfu/cell in
NBL6 equine dermal cells (American Tissue Culture Col-
lection, CCL-57). Both EHV-1 strains were titered on
rabbit kidney (RK) cells (Osterrieder et al., 1996a,b). L-M,
NBL6, and RK cell lines were grown at 37°C in Eagle’s
minimal essential medium (Gibco, Grand Island, NY),
supplemented with 10% fetal calf serum and antibiotics.
Generation of plasmid vector for expression of recom-
binant GST-gD fusion protein (rgD). The generation of
plasmid AMPGSTgD and the expression of the GST-gD
fusion protein have been described previously (Zhang et
al., 1998). Briefly, the full-length EHV-1 gD plasmid
pSP72D392 was cloned into the pGEX-4T-2 glutathione-
S-transferase (GST) expression vector (Pharmacia LKB
Biotechnology, Uppsala, Sweden) to generate the ex-
pression vector designated as AMPGSTgD. E. coli strain
DH5aF9 transformed with the expression plasmid was
propagated in 2X YT-G medium (Pharmacia LKB Biotech-
nology). The purification of GST-gD was described pre-
viously (Zhang et al., 1998).
Animals and immunization strategies. The model of
k
FIG. 7. EHV-1-specific ASC responses from mice previously immuni
were immunized i.n. with infectious EHV-1 KyA (4 3 106 pfu), HK-EHV-1
or culture medium or GST (50 mg) as control. At 8 weeks after the imm
of EHV-1 RacL11. EHV-1-specific ASC frequencies were estimated a
frequencies from 5 mice/group, representative of three independent eEHV-1 respiratory infection in mice of the H-2 haplotype
was used in this study (Alber et al., 1995). CBA/J (H-2k)
c
ifemale mice used in these studies were purchased from
Jackson Laboratories (Bar Harbor, ME) and used rou-
tinely from 5 to 12 weeks of age after a rest period of at
least 1 week. Animals were housed in filter-top cages on
vented racks under conventional conditions and given
water and mouse chow ad libitum. For immunization with
the attenuated EHV-1 strain KyA, mice were anesthetized
by halothane inhalation, and 50 ml of infected cell culture
medium containing 2 3 106 pfu KyA was instilled i.n. by
application to the external nares. Control mice received
50 ml of culture medium alone. For immunization with
ST or GST-gD, mice received multiple doses via the i.n.
oute. At the indicated times, immunized and control
ice were challenged by i.n. instillation of 1.5 3 106 pfu
f EHV-1 strain RacL11 (Zhang et al., 1998). Animals were
onitored daily for development of clinical signs such as
uffled fur, loss of body weight, lethargy, and huddling, as
escribed previously (Colle et al., 1996; Zhang et al.,
998).
Preparation of lymphocytes for ASC determinations. All
ice were divided into groups of five. On specified days
ostchallenge, the mice were terminated, and the lungs,
LN, and CLN were removed, and the spectrum of ASC
as determined by ELISPOT assay. To generate a single-
ell suspension from the lung tissue, the tissue was
ragmented with scissors and then pressed through a
0-gauge screen. After centrifugation, the cells were
esuspended in 10 ml collagenase type I/deoxyribonu-
h EHV-1 KyA and challenged i.n. with pathogenic RacL11. CBA/J mice
°C for 1 h, equivalent to 5 3 106 pfu prior to inactivation), rgD (50 mg),
on, mice were challenged i.n. with a sublethal dose (1.5 3 105 pfu/ml)
ribed under Materials and Methods. Data show the average ASC
nts, for a total of 15 animals.zed wit
KyA (56
unizatilease I solution (250:50 U/ml; Gibco-BRL) and incubated
n a shaker at 37°C for 90 min. The cells were then
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490 ZHANG ET AL.treated with 3 ml of Tris-buffered 0.83% NH4Cl solution
or 5 min at 37°C to lyse red blood cells. The cells were
esuspended in Dulbecco’s modified Eagle’s medium,
upplement with 5% calf serum and antibiotics (DMEM-5).
o generate a single-cell suspension from MLN and CLN,
he tissues were pressed through a 60-gauge screen with-
ut additional treatment. To generate a single-cell suspen-
ion from spleens, splenic tissue was pressed through a
0-gauge screen and treated with Tris–NH4Cl, as before.
ELISPOT assay. The method employed in this study
as modified from that described previously (Czerkinsky
t al., 1983; Sedgwick and Holt, 1983; Czerkinsky et al.,
988). Briefly, nitrocellulose-based microtiter 96-well
lates (Millititer-HA, Millipore Corporation, Bedford, MA)
ere coated with EHV-1 KyA-infected cell lysate (10–200
mg/ml) in phosphate-buffered saline (PBS) and incubated
in humidified chambers at 4°C overnight, or at 37°C for
2 h. The coated plates were stored at 4°C until use. For
each experimental determination, the coating buffer
(PBS) was decanted and the plates were washed three
times by rinsing with PBS. Potential remaining binding
sites were saturated with 5% fetal calf serum in PBS or
1% bovine serum albumin (Sigma Chemical Co., St.
Louis, MO) in PBS for 30 min at 37°C. Following addi-
tional washes, the lymphocytes, diluted to the appropri-
ate concentration (103 to 106 cells/well) in DMEM-5, were
added to the coated plates. Lipopolysaccharide (LPS, 5
mg/well; Calbiochem-Novabiochem, La Jolla, CA) was
added as a nonspecific activator of B cells. A control
plate of uninfected cells was also used for the assays
and was treated in the same manner as the plates of
EHV-1-infected cells.
The cells were incubated for 3 to 4 h at 37°C in 5% CO2
and then were discarded by washing with PBS contain-
ing 0.005% Tween 20 (PBST). One hundred microliters of
alkaline phosphatase-conjugated antibody was added to
each well, and the plates were incubated for 2 to 3 h at
oom temperature in humidified chambers. After thor-
ugh washing, the spots corresponding to EHV-1-spe-
ific ASC were visualized by adding 5-bromo-4-chloro-3-
ndolylphosphate p-toluidine salt (BCIP, Gibco-BRL) and
itroblue tetrazolium chloride (NBT, Gibco-BRL) as sub-
trate, according to the manufacturer’s instructions, for 5
o 30 min until the blue color developed. The nitrocellu-
ose membranes were washed for a few seconds in
ater to stop the reaction. After 2 to 24 h, EHV-1-specific
SC were counted under low (10–303) magnification in
light microscope.
Statistical analysis. Data were analyzed and tested for
ignificance by the two-tailed Student’s t test.
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